eligibility_summary
Pre-screen: newly diagnosed MM, transplant-eligible. Eligible: ≥18, consented IgG/IgA MM post-frontline autologous HCT after ≥triplet (PI+IMiD ± anti-CD38), ≥PR at screening, MRD+ at day 100 (80–160d) by clonoSEQ (>1e-5), ECOG ≤2, prior tox ≤1, adequate counts/organ function, contraception. Exclude: no trackable clonoSEQ, recent/active cancers (exceptions), investigational therapy, prior BCMA, CNS MM, allergy, uncontrolled illness/infection, pregnant/nursing, uncontrolled HIV.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm, MRD-guided maintenance after autologous transplant for newly diagnosed multiple myeloma. Intervention: Elranatamab, a subcutaneous, off‑the‑shelf bispecific antibody (BCMA×CD3) that redirects patient T cells to kill BCMA‑expressing malignant plasma cells. Mechanism: simultaneous binding to BCMA (TNFRSF17) on myeloma cells and CD3 on T cells, triggering T‑cell activation, cytotoxic synapse formation, and tumor cell apoptosis, depletes residual BCMA+ plasma cells. Targeted cells/pathways: BCMA+ myeloma/plasma cells, patient T cells via TCR/CD3 signaling. Companion intervention: clonoSEQ, an FDA‑cleared next‑generation sequencing MRD assay of Ig clonotypes to guide maintenance duration (stop after 2 consecutive MRD‑negative tests, retreat on MRD recurrence).